Overview

This trial is active, not recruiting.

Condition invasive candidiasis
Sponsor Medical University of Graz
Collaborator Medical University Innsbruck
Start date June 2016
End date September 2019
Trial size 240 participants
Trial identifier NCT02801682, KLI 561-B31

Summary

Invasive Candida infections are serious complications in immunocompromised patients including those undergoing treatment for cancer but occur also in patients treated in ICUs. Survival rate of invasive candidiasis is associated with early initiation of antifungal therapy (15% mortality rate for candidemic patients with antifungal therapy on day 0 related to the culture date of the first blood sample positive for yeasts compared to 41% for patients who received antifungal therapy on day 3). Up to date, no laboratory method or clinical decision rule is available for correct anticipation of invasive candidiasis which would avoid delays in appropriate antifungal therapy initiation. In clinical practice culture based methods (e.g. blood cultures) miss up to 50% of invasive candidiasis cases. Preemptive antifungal therapy is therefore often initiated in critically ill patients after Candida has been isolated from various non-sterile patient samples even without any sufficient evidence for invasive candidiasis. The disadvantages of this approach include over- and undertreatment of patients (up to 50% of candidemia cases are missed, and on the other hand 89% patients are treated unnecessarily), increased selective pressure for the development of antifungal resistance, potential risk of adverse drug reactions, and increased costs (expenses for antifungal therapy account for half of the antimicrobial medication budget in tertiary care hospitals). In addition, no survival benefit could be demonstrated by this strategy in ICU patients.

The aim of this study is to identify biological markers to anticipate or support the diagnosis of invasive candidiasis in ICU patients, to overcome current deficiencies in detection of invasive candidiasis and consequently to differentiate between Candida spp. colonization and invasive Candida infection. The investigators intend to examine time dependent courses of potential host and pathogen derived biomarkers as well as innate or acquired predispositions for invasive candidiasis; e.g. automated (1→3) ß- D- Glucan tests, DNA in serum blood samples, pathogen recognition receptors and serum markers like interleukin (IL)-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine, composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin, and risk factors for invasive candidiasis like underlying diseases and treatments. The study should contribute to improved assessment of ICU patients at risk for invasive candidiasis and to improved diagnosis of invasive candidiasis in ICU patients. In clinical practice the reliable differentiation between infection and colonization will allow more targeted antifungal therapy leading to enhanced antifungal treatment initiation on the one hand (in cases of true invasive candidiasis) and to reduction of unnecessary antifungal treatments and treatment costs on the other hand.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm

Primary Outcomes

Measure
Biomarkers indicating or excluding invasive Candidiasis
time frame: through study completion, an average of 2 years

Secondary Outcomes

Measure
Risk factors for Invasive Candidiasis
time frame: through study completion, an average of 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

ad 1: Inclusion Criteria: -subjects without any evidence of current or chronic infectious diseases Exclusion Criteria: - Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles) - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc) - active haematooncological diseases - HIV positivity ad 2: Inclusion criteria: -Patients with invasive Candidias/Candida sepsis as defined in recent EORTC/MSG definitions. Exclusion criteria: - glucocorticoid treatment with prednisone equivalent of ≥20mg/d - inherited neutrophil deficiency - absolute neutrophil count of ≤500cells/mm3 - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc) - active hematooncological disease - HIV positivity ad 3: Inclusion criteria: -ICU patients with sepsis and proven bacteremia (Staph. aureus or E. coli) Exclusion criteria: - Antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc) - active hematooncological disease HIV positivity ad 4: Inclusion criteria: -ICU patients without invasive candidiasis as defined above, without bacteremia and without clinical and laboratory markers of infection(e.g. intubated and mechanically ventilated patients with stroke or CPR) Exclusion criteria: - Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles) - antifungal therapy within 8 weeks prior to inclusion - immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc) - active haematooncological diseases - HIV positivity

Additional Information

Official title NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Medical University of Graz.